vs
Side-by-side financial comparison of Vericel Corp (VCEL) and VINCE HOLDING CORP. (VNCE). Click either name above to swap in a different company.
Vericel Corp is the larger business by last-quarter revenue ($92.9M vs $85.1M, roughly 1.1× VINCE HOLDING CORP.). Vericel Corp runs the higher net margin — 25.0% vs 3.2%, a 21.8% gap on every dollar of revenue. On growth, Vericel Corp posted the faster year-over-year revenue change (23.3% vs 6.2%). Vericel Corp produced more free cash flow last quarter ($12.8M vs $-5.7M). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs 6.3%).
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
VINCE. is a contemporary clothing fashion brand founded in 2002. In 2023 Authentic Brands Group purchased its intellectual property in a $76.5 million deal.
VCEL vs VNCE — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $92.9M | $85.1M |
| Net Profit | $23.2M | $2.7M |
| Gross Margin | 78.7% | 49.2% |
| Operating Margin | 24.1% | 6.4% |
| Net Margin | 25.0% | 3.2% |
| Revenue YoY | 23.3% | 6.2% |
| Net Profit YoY | 17.3% | -37.3% |
| EPS (diluted) | $0.46 | $0.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $92.9M | $85.1M | ||
| Q3 25 | $67.5M | $73.2M | ||
| Q2 25 | $63.2M | $57.9M | ||
| Q1 25 | $52.6M | $80.0M | ||
| Q4 24 | $75.4M | $80.2M | ||
| Q3 24 | $57.9M | $74.2M | ||
| Q2 24 | $52.7M | $59.2M | ||
| Q1 24 | $51.3M | $75.3M |
| Q4 25 | $23.2M | $2.7M | ||
| Q3 25 | $5.1M | $12.1M | ||
| Q2 25 | $-553.0K | $-4.8M | ||
| Q1 25 | $-11.2M | $-28.3M | ||
| Q4 24 | $19.8M | $4.3M | ||
| Q3 24 | $-901.0K | $569.0K | ||
| Q2 24 | $-4.7M | $4.4M | ||
| Q1 24 | $-3.9M | $-4.7M |
| Q4 25 | 78.7% | 49.2% | ||
| Q3 25 | 73.5% | 50.4% | ||
| Q2 25 | 73.7% | 50.3% | ||
| Q1 25 | 69.0% | 50.1% | ||
| Q4 24 | 77.6% | 50.0% | ||
| Q3 24 | 71.9% | 47.4% | ||
| Q2 24 | 69.5% | 50.6% | ||
| Q1 24 | 68.9% | 45.4% |
| Q4 25 | 24.1% | 6.4% | ||
| Q3 25 | 5.1% | 15.2% | ||
| Q2 25 | -3.2% | -7.7% | ||
| Q1 25 | -24.3% | -37.1% | ||
| Q4 24 | 24.5% | 7.2% | ||
| Q3 24 | -4.3% | 1.5% | ||
| Q2 24 | -11.5% | 9.5% | ||
| Q1 24 | -10.7% | -2.2% |
| Q4 25 | 25.0% | 3.2% | ||
| Q3 25 | 7.5% | 16.5% | ||
| Q2 25 | -0.9% | -8.3% | ||
| Q1 25 | -21.4% | -35.5% | ||
| Q4 24 | 26.3% | 5.4% | ||
| Q3 24 | -1.6% | 0.8% | ||
| Q2 24 | -8.9% | 7.4% | ||
| Q1 24 | -7.5% | -6.2% |
| Q4 25 | $0.46 | $0.21 | ||
| Q3 25 | $0.10 | $0.93 | ||
| Q2 25 | $-0.01 | $-0.37 | ||
| Q1 25 | $-0.23 | $-2.25 | ||
| Q4 24 | $0.40 | $0.34 | ||
| Q3 24 | $-0.02 | $0.05 | ||
| Q2 24 | $-0.10 | $0.35 | ||
| Q1 24 | $-0.08 | $-0.37 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $137.5M | $1.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $354.6M | $53.4M |
| Total Assets | $488.0M | $246.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $137.5M | $1.1M | ||
| Q3 25 | $135.4M | $777.0K | ||
| Q2 25 | $116.9M | $2.6M | ||
| Q1 25 | $112.9M | $607.0K | ||
| Q4 24 | $116.2M | $892.0K | ||
| Q3 24 | $101.7M | $711.0K | ||
| Q2 24 | $102.5M | $739.0K | ||
| Q1 24 | $110.6M | $357.0K |
| Q4 25 | $354.6M | $53.4M | ||
| Q3 25 | $321.9M | $49.3M | ||
| Q2 25 | $306.8M | $37.2M | ||
| Q1 25 | $295.5M | $41.8M | ||
| Q4 24 | $292.0M | $57.1M | ||
| Q3 24 | $257.5M | $52.4M | ||
| Q2 24 | $243.0M | $51.7M | ||
| Q1 24 | $233.9M | $47.2M |
| Q4 25 | $488.0M | $246.0M | ||
| Q3 25 | $453.3M | $239.0M | ||
| Q2 25 | $435.6M | $218.0M | ||
| Q1 25 | $424.6M | $222.7M | ||
| Q4 24 | $432.7M | $254.7M | ||
| Q3 24 | $390.4M | $253.6M | ||
| Q2 24 | $376.8M | $223.1M | ||
| Q1 24 | $356.7M | $225.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $15.0M | $-5.1M |
| Free Cash FlowOCF − Capex | $12.8M | $-5.7M |
| FCF MarginFCF / Revenue | 13.8% | -6.7% |
| Capex IntensityCapex / Revenue | 2.4% | 0.7% |
| Cash ConversionOCF / Net Profit | 0.65× | -1.86× |
| TTM Free Cash FlowTrailing 4 quarters | $24.7M | $4.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $15.0M | $-5.1M | ||
| Q3 25 | $22.1M | $4.2M | ||
| Q2 25 | $8.2M | $-11.8M | ||
| Q1 25 | $6.6M | $22.7M | ||
| Q4 24 | $22.2M | $6.4M | ||
| Q3 24 | $10.2M | $-3.2M | ||
| Q2 24 | $18.5M | $-3.9M | ||
| Q1 24 | $7.2M | $14.8M |
| Q4 25 | $12.8M | $-5.7M | ||
| Q3 25 | $19.5M | $2.1M | ||
| Q2 25 | $81.0K | $-13.2M | ||
| Q1 25 | $-7.6M | $21.2M | ||
| Q4 24 | $8.5M | $5.1M | ||
| Q3 24 | $-9.2M | $-3.9M | ||
| Q2 24 | $1.8M | $-4.6M | ||
| Q1 24 | $-6.8M | $14.2M |
| Q4 25 | 13.8% | -6.7% | ||
| Q3 25 | 28.8% | 2.9% | ||
| Q2 25 | 0.1% | -22.9% | ||
| Q1 25 | -14.5% | 26.5% | ||
| Q4 24 | 11.2% | 6.4% | ||
| Q3 24 | -15.9% | -5.2% | ||
| Q2 24 | 3.4% | -7.8% | ||
| Q1 24 | -13.3% | 18.9% |
| Q4 25 | 2.4% | 0.7% | ||
| Q3 25 | 3.9% | 2.9% | ||
| Q2 25 | 12.9% | 2.5% | ||
| Q1 25 | 27.0% | 1.9% | ||
| Q4 24 | 18.3% | 1.6% | ||
| Q3 24 | 33.5% | 0.9% | ||
| Q2 24 | 31.8% | 1.3% | ||
| Q1 24 | 27.3% | 0.7% |
| Q4 25 | 0.65× | -1.86× | ||
| Q3 25 | 4.35× | 0.35× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.12× | 1.48× | ||
| Q3 24 | — | -5.61× | ||
| Q2 24 | — | -0.89× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
VNCE
| Vince Wholesale | $52.0M | 61% |
| Vince Direct To Consumer | $33.1M | 39% |
